Download PDF
Drug Res (Stuttg) 2020; 70(06): 280-285
DOI: 10.1055/a-1150-2372
Original Article

Pseudomonas Aeruginosa as the Main Causative Agent of Osteomyelitis and its Susceptibility to Antibiotics

Natalya N. Pliska
1   Research Institute of Traumatology and Orthopedics, Ministry of Health of the Republic of Kazakhstan, Nur-Sultan, Kazakhstan
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Surgical activity is increasing in the treatment of many types of fractures, the use of various metal structures, and the potential for infection with the development of osteomyelitis accordingly increases. The urgency of the problem is due to the fact that this disease is the most expensive medical problem, especially when it comes to prosthetics of large joints, with socially significant losses and the occurrence of disability in patients of working age, it requires long-term treatment. The aim of this study was to study one of the most complex pathogens of life-threatening infections due to its high virulence and ability to adapt to changing environmental conditions, in particular the action of antibacterial drugs and the study of its sensitivity to certain groups of antimicrobial drugs. The results of the study showed that over the three years of observation in 2017–2019, the average value of Pseudomonas aeruginosa in the amount of 10.8% was established in the etiology of osteomyelitis. The revealed sensitivity of Pseudomonas aeruginosa is preserved to fluoroquinolone – levofloxanin, aminoglycosides-amikacin, gentamicin, carbapenems – meropenem, doripenem. All of the above drugs can be used as empirical therapy. During this period, a significant decrease in sensitivity was found, which reached in 2019 for cefepime – 51.9%, pefloxacin – 55.8%, ertapenem – 59.7%. The success of the treatment of this pathology directly depends on the timely microbiological diagnosis and the choice of patient treatment tactics with the appointment of effective antibacterial therapy, with an adequate exposure of antibiotic.

Keywords

diagnostics - molecular pharmacology - pharmaceutics


Publication History

Received: 03 March 2020

Accepted: 30 March 2020

Article published online:
17 April 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Winkler T, Trumpusch A, Renz N. Classification and algorithm for the diagnosis and treatment of periprosthetic hip infection. Traumatology and Orthopedics of Russia 2016; 1: 33-45
    PubMedGoogle Scholar
  • 2 Tikhilov M, Shubnyakov II, Kovalenko AN. The structure of the early revisions of the hip joint replacement. Traumatology and Orthopedics of Russia 2014; 2: 5-13
    PubMedGoogle Scholar
  • 3 Bozhkova SA, Razorenov VL, Petrova TM. Microbiological monitoring is the basis of a rational strategy and tactics of antibiotic therapy for infection of bones and prosthetic joints. Togliatti Medical Council 2011; 3–4: 33-42
    PubMedGoogle Scholar
  • 4 Corvec S, Portillo ME, Pasticci BM. et al. Epidemiology and new Developments in the diagnosis of prosthetic joint infection. International Journal of Artificial Organs 2012; 35: 923-934
    CrossrefPubMedGoogle Scholar
  • 5 Zimmerli W, Trampuz A Biomaterials-associated infection: A perspective from the clinic. In: T.F. Moriarty, S.A.J. Zaat, H. Busscher, Eds., Biomaterials Associated Infection: Immunological Aspects and antimicrobial Strategies. New York: Springer; London: Heidelberg Dordrecht, 2013: 3-24
    PubMed
  • 6 Zimmerli W, Trampuz A, Ochsner P. Prosthetic-joint infections. New England Journal of Medicine 2004; 351: 1645-1654
    CrossrefPubMedGoogle Scholar
  • 7 Geipel U. Pathogenic organisms in hip joint infections. International Journal of Medical Sciences 2009; 6: 234-240
    PubMedGoogle Scholar
  • 8 Ilyukevich GV, Smirnov VM, Levshina NN. Antibiotic resistance of hospital strains of Pseudomonas aeruginosa and optimization of the choice of antimicrobial therapy in intensive care and resuscitation departments. Infections and Antimicrobial Therapy 2003; 7: 63-67
    PubMedGoogle Scholar
  • 9 Rozova LV, Annuals NV. Comparative characteristics of the species composition of microorganisms in chronic post-traumatic and hematogenous osteomyelitis. Orthopedics Genius 2014; 2: 56-59
    PubMedGoogle Scholar
  • 10 The state of antibiotic resistance of gram-negative pathogens of nosocomial infections in the intensive care unit and intensive care unit, 1997. http://www.antibiotic.ru/iacmac/ru/pub/letters/argrmnoz/
    PubMed
  • 11 Rudnov VA. Antibiotic therapy for hospital infections caused by P. Aeruginosa. Russian Medical Journal 2005; 13: 485
    PubMedGoogle Scholar
  • 12 Harris AD, Perencevich E, Rohgmann M. et al. Risk factors for piperacillin-tazobactam-resistant pseudomonas aeruginosa among hospitalized patients. Antimicrobial Agents and Chemotherapy 2002; 46: 854-858
    CrossrefPubMedGoogle Scholar
  • 13 Bozic KJ, Lau E, Kurtz S. et al. Patient-related risk factors for periprosthetic joint infection and postoperative mortality following total hip arthroplasty in edicare patients. Journal of Bone and Joint Surgery 2012; 94: 794-800
    CrossrefPubMedGoogle Scholar
  • 14 Perka C, Haas N. Periprothetische infektion. Der Chirurg 2011; 82: 218-226
    CrossrefPubMedGoogle Scholar
  • 15 Roy-Burman A, Savel RH, Racine S. et al. Type III protein secretion is associated with death in lower respiratory and systemic pseudomonas aeruginosa infections. Journal of Infectious Diseases 2001; 183: 1767-1774
    CrossrefPubMedGoogle Scholar
  • 16 Turner PJ. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): A global overview. Journal of Antimicrobial Chemotherapy 2000; 46: 9-23
    PubMedGoogle Scholar
  • 17 Pozdeev OK. Medical Microbiology. Moscow: Geotarmed; 2001
    Google Scholar
  • 18 Privolnev VV, Rodin AV, Karakulina EV. Topical use of antibiotics in the treatment of bone infections. Clinical Microbiology and Antimicrobial Chemotherapy 2012; 14: 118-131
    PubMedGoogle Scholar
  • 19 Winkler T, Trampush A, Renz N. et al. Classification and algorithm for the diagnosis and treatment of periprosthetic hip infection. Traumatology and Orthopedics of Russia 2016; 1: 33-45
    PubMedGoogle Scholar
  • 20 Order of the Ministry of Health of the USSR of 04.22.1985. No. 535. On the unification of microbiological research methods used in clinical diagnostic laboratories of medical institutions. http://www.libussr.ru/doc_ussr/usr_12667.htm
    PubMed
  • 21 Determination of the sensitivity of microorganisms to antimicrobial agents, 2014. http://www.antibiotic.ru/minzdrav/files/docs/clrec-dsma2014.pdf
    PubMed
  • 22 Sergienko VI, Bondareva IB. Mathematical statistics in clinical studies. Moscow: GEOTAR Medicine; 2000
    Google Scholar
  • 23 Vincent J-L. Microbial resistance: lessons from the EPIC study. Intensive Care Medicine 2000; 26: S003-S008
    CrossrefPubMedGoogle Scholar
  • 24 Trouillet JL, Chastre J, Vuagnant A. et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. American Journal of Respiratory and Critical Care Medicine 1998; 157: 531-539
    PubMedGoogle Scholar
  • 25 Maksimkina EA, Vaskova LB, Musina NZ. et al. Budget impact analysis of antipsychotic drugs in the hospital treatment of schizophrenia. Per Tche Quim 2019; 16: 509-515
    PubMedGoogle Scholar
  • 26 Dossa AB, Silva YPD. Anti-hypertension drugs: Action in the organism and environmental contamination. Per Tche Quim 2018; 15: 527-549
    PubMedGoogle Scholar